Integrated Filing — IndAS



General information about company

Scrip Code 500087
NSE Symbol CIPLA
MSEI Symbol NOTLISTED
ISIN INE059A01026
Name of company CIPLA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 23-07-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 24-06-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 23-07-2026   09:15:00
End date and time of board meeting 23-07-2026   13:00:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 5,07,768.00 5,07,768.00
Other income 24,275.00 24,275.00
Total income 5,32,043.00 5,32,043.00
2 Expenses
(a) Cost of materials consumed 1,03,857.00 1,03,857.00
(b) Purchases of stock-in-trade 65,115.00 65,115.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 2,154.00 2,154.00
(d) Employee benefit expense 91,496.00 91,496.00
(e) Finance costs 568.00 568.00
(f) Depreciation, depletion and amortisation expense 16,939.00 16,939.00
(f) Other Expenses
1 Other Expenses 1,36,552.00 1,36,552.00
Total other expenses 1,36,552.00 1,36,552.00
Total expenses 4,16,681.00 4,16,681.00
3 Total profit before exceptional items and tax 1,15,362.00 1,15,362.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 1,15,362.00 1,15,362.00
6 Tax expense
7 Current tax 30,789.00 30,789.00
8 Deferred tax (1,643.00) (1,643.00)
9 Total tax expenses 29,146.00 29,146.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 86,216.00 86,216.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 86,216.00 86,216.00
17 Other comprehensive income net of taxes 6,728.00 6,728.00
18 Total Comprehensive Income for the period 92,944.00 92,944.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 16,157.00 16,157.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 10.67 10.67
Diluted earnings (loss) per share from continuing operations 10.67 10.67
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 10.67 10.67
Diluted earnings (loss) per share from continuing and discontinued operations 10.67 10.67
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2. The National Pharmaceutical Pricing Authority (“NPPA”) issued several demand notices to the Company commencing from the year 1998 seeking recovery of alleged overcharge regarding scheduled drugs under the Drugs (Prices Control) Orders-1995 (“DPCO”). In 1999 and 2000, the Company filed writ petitions before the Hon’ble Bombay High Court (“Bombay HC”) challenging inclusion of certain drugs under DPCO and challenging the demand notices issued by NPPA demanding payment of alleged overcharged amounts. On 31st August, 2001, by way of its common judgment, the Bombay HC decided the writ petitions in favor of the Company, thereby holding that these drugs do not fall within the purview of DPCO and also quashed the demand notices raised by NPPA. The NPPA appealed the order to the Hon’ble Supreme Court (“SC”). On 1st August, 2003, SC set aside the Bombay HC judgment and remanded the matter to the Bombay HC for being considered afresh by it. Further, the SC stayed recovery of 50% of the alleged overcharged amounts subject to payment of the remaining 50% of the alleged overcharged amounts pending fresh determination by the Bombay HC. Accordingly, in terms of SC’s Judgment the Company deposited an amount of Rs. 175.08 Crores with NPPA, representing 50% of the alleged overcharged amounts in respect of demand notices raised till 2003. Post 2003, the Company continued to receive demands (“Subsequent demands”) alleging overcharging. These demands included several duplicate demands. In 2019, the Company applied to the Bombay HC to amend its pleadings to include: (i) subsequent demands (ii) take on record the NPPA/ Government of India’s RTI response on unavailability of any records pertinent to and what should have been the basis for inclusion of these drugs under the DPCO (iii) deduction of trade margin of 16% from outstanding demands (as having not accrued to the Company, as manufacturer) basis the Allahabad HC’s TC Healthcare judgment (iv) re-calculation of interest from the due date of demand notice and (v) duplication of several demands. The Bombay HC vide order dated 23rd February, 2024 allowed the amendment conditional upon the Company depositing 50% of the subsequent demands raised. The Company appealed the Bombay HC order in a special leave petition before the SC. On 19th April, 2024, the SC was pleased to issue notice and the matter is pending to be heard further. Without prejudice to the Company’s position of no amount being due towards the alleged overcharge (principal) or consequential interest, on 15th July 2025 the Company has voluntarily deposited with the NPPA an additional amount of Rs. 27.07 Crores towards the principal against certain demand notices. The Company has reviewed all the notices/communications received which are attributable to the Company and are under litigation. After removing duplications as indicated above, the amount covered by the notices/communications aggregates to Rs. 2,011 Crores with the principal of Rs. 863 Crores and interest of Rs. 1,148 Crores. The above demand notices do not include certain demand notices, jointly addressed to Okasa Pharma Private Limited or Okasa Limited (related parties and promoter group companies, collectively “Okasa), and the Company. These pertain to products manufactured by Okasa and marketed by Cipla. The Company responded to these demand notices (amounting to Rs. 9.96 Crores), stating that it is not the manufacturer and therefore not liable. These demand notices are also subject matter under Business Transfer Agreement between Okasa and Cipla’s subsidiary which excludes the DPCO liability as part of the business transferred by Okasa to the subsidiary. Further, Okasa has independently challenged these demand notices before the Hon’ble Bombay HC. The Company has been legally advised that it expects a favourable outcome in respect of these matters and therefore no provision is considered necessary in respect of the aforementioned demand notices received till date including demand notices addressed singly/ jointly w.r.t transactions with Okasa. 3. The paid-up equity share capital stands increased to Rs. 161.57 Crores (80,78,45,316 equity shares of face value Rs. 2 each) upon allotment of 54,903 equity shares and 7,782 equity shares of Rs. 2 each pursuant to ESOS 2013-A and “Cipla ESAR Scheme 2021” respectively during the quarter ended 30th June 2026. 4. The figures for the quarter ended 31st March, 2026 is the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year. 5. Effective 21st November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. Pursuant to the Company's assessment performed as at 31st December, 2025, the Company recognized an incremental gratuity liability arising from past service cost and an increase in leave liability aggregating Rs. 244.37 Crores, primarily due to the revised definition of “wages” applicable to employees and contract labour. Considering the materiality and non-recurring nature of this change, the Company has presented such incremental expenses under “Exceptional Item” in the financial results. 6. During the quarter and year ended 31st March, 2026, the Company has recorded an impairment of Rs. 31.00 Crores in the financial results in respect of an associate, on account of change in certain business conditions and market dynamics. 7. The Board of Directors of the Company, at its meeting held on 19th March 2026, approved the Scheme of Amalgamation of Inzpera Healthsciences Limited, a wholly owned subsidiary of the Company (the “Transferor Company”), with Cipla Limited (the “Transferee Company” or the “Company”). The Scheme of Amalgamation is subject to the necessary approvals required under the Companies Act, 2013, including the approval of the Hon’ble National Company Law Tribunal (“NCLT”), Mumbai. The Company has filed the Scheme with the Hon’ble NCLT and its approval is awaited. 8. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 23rd July, 2026. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss 2,515.00 2,515.00
Total Amount of items that will not be reclassified to profit and loss 2,515.00
2 Income tax relating to items that will not be reclassified to profit or loss 633.00 633.00
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss 6,476.00 6,476.00
Total Amount of items that will be reclassified to profit and loss 6,476.00
4 Income tax relating to items that will be reclassified to profit or loss 1,630.00 1,630.00
5 Total Other comprehensive income 6,728.00 6,728.00